Matthew Cardinal has more than 15 years of experience in biologics, drug and medical device development. Matthew functions as a team leader in the design, planning, and management of development strategies for hematology, immunology, gene therapy, regenerative medicine, and infectious disease/vaccine programs. Matthew supports all development lifecycles, from pre-IND through registration, with a focus on translational clinical research and quantitative drug development. Matthew has a specific background and interest in indications for rare diseases and AAV gene therapy, including hematology and rare immunodeficiencies. At a technical level, Matthew is experienced in scientific writing, data analysis, and presentation.
Prior to joining Halloran, Matthew was a clinical development lead for early-phase rare disease programs at Pfizer, where he helped lead the development of marstacimab (anti-TFPI for hemophilia, now in Phase 3), and Factor Xa (hemorrhagic stroke), along with pre-clinical assets in sickle cell disease and AAV gene therapy for rare immunology indications. Matthew also was a clinical development lead for meningococcal and sepsis vaccines at Novartis where he co-led an emergency vaccination Treatment IND for a Meningitis B outbreak at Princeton University and the University of California –Santa Barbara with the Center for Disease Control and Prevention. Matthew has additional experience as a clinical scientist in regenerative medicine for Shire/Advanced BioHealing and as a medical device engineer for Johnson & Johnson. Matthew earned a Bachelor of Science (B.S.) and Master of Engineering (M.E.) in Biomedical Engineering (BME) from Worcester Polytechnic Institute.